Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow An erratum has been published
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (11)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Wills, A.J.
Right arrow Articles by Reilly, M.M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wills, A.J.
Right arrow Articles by Reilly, M.M.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Q J Med 2001; 94: 403-406
© 2001 Association of Physicians


Review

Refsum's disease

A.J. Wills1,3,, N.J. Manning2 and M.M. Reilly3

1 From the Neurology Department, University Hospital Nottingham, Nottingham, 2 Department of Chemical Pathology and Neonatal Screening, The Children's Hospital, Sheffield, and 3 Department of Clinical Neurology, The National Hospital for Neurology and Neurosurgery, London, UK


    Introduction
 
Refsum's disease (hereditary motor and sensory neuropathy type IV) is a rare autosomal recessive condition first characterized by Sigvald Refsum in 1945. He initially chose the name heredoataxia hemeralopica polyneuritiformis,1 subsequently amending this to heredopathia atactica polyneuritiformis.2 Thankfully, the eponymous version now predominates in the literature, and these earlier terms have been largely abandoned.


    Biochemistry
 
Refsum's disease is caused by defective alpha oxidation of phytanic acid (3,7,11,15 tetramethylhexadecanoic acid), a branched-chain fatty acid present in a wide range of foodstuffs including dairy products, some meats and fish.3 The defective enzyme is phytanoyl-coenzyme A hydroxylase, which normally catalyses the second step in the breakdown of phytanic to pristanic acid using the CoA derivative as a substrate (the first step in alpha oxidation is the conversion of phytanic acid to phytanoyl CoA by Phytanoyl CoA ligase).4 This results in accumulation of phytanic acid, with elevated levels in blood and other tissues including . . . [Full Text of this Article]


    Clinical features
 

    Diagnosis
 

    Genetics
 

    Treatment
 

    Conclusion
 

    Notes
 

    References
 

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
BMJ Case ReportsHome page
S. A Thompson, J. Calvin, S. Hogg, S. Ferdinandusse, R. J A Wanders, and R. A Barker
Relapsing encephalopathy in a patient with {alpha}-methylacyl-CoA racemase deficiency
BMJ Case Reports, February 2, 2009; 2009(jan27_1): bcr0820080814 - bcr0820080814.
[Abstract] [Full Text]


Home page
J. Neurol. Neurosurg. PsychiatryHome page
S A Thompson, J Calvin, S Hogg, S Ferdinandusse, R J A Wanders, and R A Barker
Relapsing encephalopathy in a patient with {alpha}-methylacyl-CoA racemase deficiency
J. Neurol. Neurosurg. Psychiatry, April 1, 2008; 79(4): 448 - 450.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Neuroradiol.Home page
V. Choksi, E. Hoeffner, E. Karaarslan, C. Yalcinkaya, and S. Cakirer
Infantile Refsum Disease: Case Report
AJNR Am. J. Neuroradiol., November 1, 2003; 24(10): 2082 - 2084.
[Abstract] [Full Text] [PDF]